Objective To identify factors associated with treatment delays in pediatric patients with convulsive refractory status epilepticus (rSE).
Status epilepticus (SE) is one of the most common neurologic emergencies, affecting approximately 5 to 20 children per 100,000 per year. [1] [2] [3] Mortality in pediatric SE is approximately 0% to 3% in the short term 1, 4, 5 and approximately 7% in the long term. 6 Sequelae, such as neurologic, cognitive, and behavioral problems, are common. 7 The main predictors of outcome are age, etiology, and duration of SE, 5, 7, 8 but duration of SE is often most easily modified.
To minimize seizure duration, SE guidelines suggest timely treatment with rapid escalation of antiepileptic drugs (AEDs) if needed. 9, 10 Basic research and clinical studies suggest that delays in medication administration are associated with greater resistance to treatment and worse outcomes. [11] [12] [13] [14] [15] [16] However, time to treatment in SE is often longer than guidelines recommend in adults 17, 18 and children. [18] [19] [20] In previous studies from the Pediatric Status Epilepticus Research Group (pSERG), we showed that time to the administration of the first AEDs was slower than guideline recommendations, 21 and that treatment initiation delays were associated with worsened outcomes. 21a However, there are limited data regarding factors associated with treatment delays. Previously, we showed that the time to AED administration was similar in patients with and without a prior diagnosis of epilepsy, 22 but it is unknown whether there are other factors associated with treatment delays that might be amenable to intervention in efforts to reduce time to treatment in SE.
We aimed to address this gap in knowledge by identifying factors independently associated with delays to administration of AEDs in pediatric patients with convulsive refractory SE (rSE). We evaluated a series of factors potentially associated with delays to administration of treatment: type of rSE (continuous vs intermittent), site of rSE onset (in hospital vs out of hospital), time of day at onset (day vs night), period in the academic year (first half vs last half), race (white vs nonwhite), and increased awareness of the existence of marked delays in rSE treatment (no vs yes).
Methods

Study design
We performed a prospective, observational study within pSERG, an ongoing multicenter consortium that aims to generate data to inform clinical decision-making and improve outcomes in pediatric rSE. 23 Detailed data on time to treatment, 21 differences between patients with and without a prior diagnosis of epilepsy, 22 and the association of treatment delays with outcomes 21a have been previously reported.
Standard protocol approvals, registrations, and patient consents The study was approved by the institutional review boards at each participating center.
Patients
This study involved patients with rSE. The inclusion criteria were as follows: (1) age from 1 month to 21 years; (2) admission between June 1, 2011, and March 1, 2017; and (3) focal or generalized convulsive seizures at onset that continued after administration of at least 2 AEDs, including at least one nonbenzodiazepine (non-BZD) AED or the use of a continuous infusion to treat rSE. Exclusion criteria were as follows: (1) nonconvulsive SE detected on EEG without convulsive seizures at onset, (2) nonconvulsive SE with motor manifestations limited to infrequent myoclonic jerks, and (3) insufficient basic demographic or clinical data. In summary, for the purposes of this study, rSE refers to a single convulsive seizure or a cluster of convulsive seizures without return to baseline that did not respond to administration of at least 2 AEDs, including at least one non-BZD AED or the use of a continuous infusion. If more than one rSE episode occurred during the study period, only the first episode was included in the statistical analysis.
Variables
The primary outcome was time to administration of AEDs: first BZD, first non-BZD AED, and, for patients who received continuous infusion, time to first continuous infusion. The time to treatment was determined based on information provided by family and emergency medical services (EMS) for out-of-hospital onset and from provider information and hospital records once in the hospital. To minimize bias, we cross-referenced time information between all available sources of information. We evaluated the following dichotomous variables potentially associated with delays in treatment administration: type of rSE (continuous vs intermittent), site of rSE onset (in hospital vs out of hospital), time of day at onset (day vs night), period in the academic year (first half vs last half), race (white vs nonwhite), and increased awareness of the existence of marked delays in rSE treatment (no vs yes). Awareness of delays in treatment administration were dichotomized into the period 2011-2014 (when the existence of delays to treatment was a study question within pSERG) and the period 2015-2017 (when the existence of treatment delays was demonstrated 21 ) as a rough surrogate marker of awareness. Time of day was dichotomized into day (8 AM to 8 PM) and night (8 PM to 8 AM) based on office working hours, although working schedules may vary among hospitals. The academic year was dichotomized into first half (July to December) and second half (January to June) to address the education and experience of new residents, although we Glossary AED = antiepileptic drug; BZD = benzodiazepine; CI = confidence interval; EMS = emergency medical services; HR = hazard ratio; p 25 -p 75 = 25th-75th percentiles; pSERG = Pediatric Status Epilepticus Research Group; rSE = refractory status epilepticus; SE = status epilepticus.
acknowledge that the degree of reliance on residents may be different among institutions and at different times of the day within institutions. Racial inequalities in health and access to health care are well documented, and race is an indirect marker of access to health care. 24, 25 rSE was classified as continuous when it consisted of a single prolonged seizure and as intermittent when it consisted of repeated seizures without return to baseline, as based on all available information. We also controlled for potential confounders in the multivariable analysis: etiology (structural vs nonstructural vs unknown), prior diagnosis of epilepsy (no vs yes), prior episode of SE (no vs yes), and age (in years). Potential reasons for delay in time to treatment were considered based on prior knowledge.
Statistical analysis
Descriptive statistics summarized demographic and basic clinical features. We compared quantitative variables among 2 groups with the Wilcoxon rank sum test and among more than 2 groups with the Kruskal-Wallis test. Times to administration of AEDs were analyzed using Cox proportional hazard regression models. We evaluated the proportional hazard assumption with log-log and residuals graphs for each Cox model. There were no major departures from the proportional hazards assumptions. Because the location of rSE onset is a potential effect modifier, we supplemented our analysis of the entire population with a stratified analysis dividing patients by location of rSE onset: out of hospital vs in hospital. Within each population, a patient may have received treatment at various sites (home, by EMS, non-pSERG hospital, and pSERG hospital). Unless stated otherwise, quantitative variables are presented as median (25th-75th percentiles [p 25 -p 75 ]) and categorical variables are presented as number and percentage. By convention, a 2-sided α level was set at 0.05 to denote statistical significance. We controlled for multiple comparisons with the Benjamini and Hochberg false discovery rate, with a threshold (q value) of 0.05. 26 False discovery rate controls for expected proportion of false discoveries relative to total discoveries, in order to control for multiple comparisons across multiple tests. 26 All analyses were performed using R: a language and environment for statistical computing (Vienna, Austria), 27 RStudio, 28 and the packages gmodels, 29 figure 2 ). None of the studied factors were associated with a delayed administration of continuous infusion.
Stratification by site of rSE onset
Out-of-hospital onset A total of 141 patients had out-of-hospital rSE onset (tables e-2 and e-3, links.lww.com/WNL/A431 e-1C ). In the population with out-of-hospital rSE onset, the factor associated with more delay to the first BZD was no prior SE (HR 2.32, 95% CI 1.58-3.42; p = 0.0053). The factor associated with more delay to the first non-BZD AED was intermittent rSE (HR 2.33, 95% CI 1.58-3.42; p = 0.0002). None of the studied factors were associated with a delayed administration of continuous infusions (table e-4, figure 3 ).
In-hospital onset
A total of 78 patients had in-hospital rSE onset (tables e-5 and e-6, links.lww.com/WNL/A431 None of the studied factors were associated with a delayed administration of the first BZD, first non-BZD AED, or first continuous infusion (tables 2 and e-7).
Additional information on our study population is presented in supplemental results (links.lww.com/WNL/A433).
Discussion
Intermittent rSE and out-of-hospital rSE onset are independently associated with longer delays to administration of the first BZD and the first non-BZD AED in pediatric rSE. Among patients with out-of-hospital onset, no prior SE episode was independently associated with longer delays to administration of the first BZD, and intermittent rSE was independently associated with longer delays to administration of the first non-BZD AED. These factors identify potential targets for intervention to reduce time to treatment.
We found more delays to treatment administration when rSE was intermittent. A potential explanation for treatment delay may include the perception that the episode is spontaneously resolving if clinical seizures wax and wane rather than occurring continuously. This result identifies a potential target for intervention with education on the need for emergent treatment even if seizures are not occurring continuously but intermittently. Most delays in treatment occur out of the hospital and, as in other series, 12,21 most SE and rSE episodes started out of the hospital. Hospitals currently have limited ability to start managing and treating patients with rSE continuously in the prehospital setting. Furthermore, in some states, rescue treatment via the EMS crew is restricted. Abbreviations: AED = antiepileptic drug; BZD = benzodiazepine; CI = continuous infusion. Data are n (%) or median (25th-75th percentiles). a Percentages do not add up to 100 because the categories are not mutually exclusive.
Families and EMS may not be aware of the importance of a timely treatment. Therefore, delays in treatment administration may be attributable to complexities of a fragmented health care system and operational capacity (e.g., prompt availability of AEDs, pharmacy processing times) more than to physician willingness to promptly administer treatment. Among patients with out-of-hospital onset, those who received their first BZD at home or by EMS had much shorter time to first BZD than patients who received their first BZD at the hospital. Ensuring prompt initial treatment at home or by EMS might greatly reduce overall time to initial treatment. Because delays in treatment administration occur even in patients with a diagnosis of epilepsy, 22 educational programs that emphasize the need for an emergent treatment of prolonged seizures out of the hospital may greatly reduce overall time to treatment. Despite most delays occurring out of the hospital, there is also room for improvement in the time to treatment for patients with in-hospital rSE onset. An active educational and interventional campaign focusing on the risk factors for delays and establishing acute treatment pathways similar to that of stroke or myocardial infarction care may reduce time to treatment.
The longer the seizures last, the more resistant they become to the initial SE treatments. The time-dependent pharmacoresistance to BZDs has been found in animal models, [34] [35] [36] and clinical studies have shown that as seizures last longer, they often become self-sustained and progressively more resistant to treatment. [11] [12] [13] In a series of 66 patients with generalized tonic-clonic SE, one of the factors associated with death was time to treatment administration. 37 Within the pSERG series, AED administration delays are associated with higher mortality and poorer outcomes. 21a Despite the association of time to treatment with outcomes, delays in treatment administration still occur. In a series of 542 pediatric patients, the median time from arrival at the hospital to administration of a non-BZD AED was 24 minutes. 19 In a study of 625 adults and 264 children with SE, approximately 60% of patients received their first AED after 30 minutes and approximately 25% after 60 minutes. 18 Within the pSERG series, we previously showed that the median time to first, second, and third AED was 28 minutes, 40 minutes, and 59 minutes, respectively, 21 and treatment delays occurred even in patients already diagnosed with epilepsy. 22 The current analysis with 219 patients establishes that intermittent rSE and rSE onset out of hospital are independently associated with more delays to treatment administration.
The following factors were not independently associated with more delays in time to treatment: time of day or night, the first (2011-2014) vs the second (2015-2017) part of the cohort period, first half vs last half of the academic year, and white vs nonwhite race. Dichotomizing variables leads to some loss of information, but the number of predictors in the regression models had to be limited to prevent overfitting.
Our study population may or may not be representative of all children with SE. The pSERG consortium focuses on convulsive rSE, and our results are therefore not necessarily generalizable to patients with nonrefractory SE or with nonconvulsive SE. Times and the classification of rSE as continuous or intermittent were evaluated based on information provided by family and EMS for out-of-hospital onset and from provider information and hospital records once in the hospital. Because this method of data acquisition is subject to Abbreviations: AED = antiepileptic drug; BZD = benzodiazepine; CI = confidence interval; HR = hazard ratio; rSE = refractory status epilepticus.
information and recall bias, we cross-referenced information with families, EMS records, nurses, and medication administration records when available to reduce bias. There are limitless potential factors accounting for time to treatment administration. We selected the most relevant potential predictors and potential confounders based on prior knowledge. Including more variables in the model might have resulted in overfitting and unstable results. In contrast, our results were stable in the whole population, the in-hospital and out-of-hospital subgroups, and robust to sensitivity analyses. Our results were also robust to correction for multiple testing.
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Study funding
Study question
What factors are independently associated with treatment delays in pediatric refractory convulsive status epilepticus (rSE)?
Summary answer
Intermittent rSE and out-of-hospital rSE onset are independently associated with treatment delays.
What is known and what this paper adds
The duration of status epilepticus (SE) episodes is the most modifiable of the major predictors of outcomes, thus clinical guidelines recommend rapid initiation of antiepileptic drug (AED) therapy. This study identifies the key factors associated with delays in initiating rSE treatment.
Participants and setting
This multicenter study examined 219 pediatric patients (53% male; median age, 3.9 years; interquartile age range, 1.2-9.5 years) who were admitted to hospitals between June 1, 2011, and March 1, 2017. The patients experienced focal or generalized convulsive seizures that continued after the administration of ≥2 AEDs, including ≥1 nonbenzodiazepine (non-BZD) drug or the use of a continuous infusion.
Design, size, and duration For each patient, this prospective study determined the time between seizure onset and initiation of the first BZD AED, initiation of the first non-BZD AED, and initiation of continuous AED infusion. This study also collected information on variables including the type of rSE and whether rSE onset occurred out-of-hospital.
Main results and the role of chance Intermittent rSE and out-of-hospital rSE onset were both independently associated with greater delays in the initiation of the first BZD and initiation of the first non-BZD AED. No examined factor was associated with delays in the initiation of continuous AED infusion.
Bias, confounding, and other reasons for caution For cases with out-of-hospital onset, information prior to hospital admission was collected from family and emergency medical services and might have been subject to recall bias. Many factors that may influence treatment delays were not available.
Generalizability to other populations
This study's results may not be generalizable to children with non-refractory or non-convulsive SE.
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